Tapering and discontinuation of methotrexate in patients with RA treated with TNF inhibitors: Data from the DREAM registry

RMD Open

Volumn 1, Issue 1, 2015, Pages

  Manders, Sofie H M ^a   Van De Laar, Mart A F J ^b   Rongen Van Dartel, Sanne A A ^a   Bos, Reinhard ^c   Visser, Henk ^d   Brus, Herman L ^e   Jansen, Tim ^f   Vonkeman, Harald E ^b   Van Riel, Piet L C M ^a   Kievit, Wietske ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF TWENTE   (Netherlands)

^c MEDICAL CENTER LEEUWARDEN   (Netherlands)

^d Department of Rheumatology ^*  (Netherlands)

^e Department of Rheumatology   (Netherlands)

^f VieCuri   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85018193107     PISSN: None     EISSN: 20565933     Source Type: Journal    
DOI: 10.1136/rmdopen-2015-000147     Document Type: Article

References (19)

1. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
2. Klareskog L, Van Der Heijde D, De Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
3. Van Der Heijde D, Klareskog L, Rodriguez-Valverde V, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006;54:1063-74.
4. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
5. Harrison MJ, Lunt M, Verstappen SMM, et al. Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis. Health Qual Life Outcomes 2010;8:21.
6. Verstappen SM, Bakker MF, Heurkens AHM, et al. Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study. Ann Rheum Dis 2010;69:1044-8.
7. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
8. Prevoo ML, Van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
9. Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
10. Van Der Maas A, Lie E, Christensen R, et al. Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study. Ann Rheum Dis 2013;72:1800-5.
11. Seltman HJ. Mixed models: a flexible appraoch to correlated data. In Experimental Design for Behavioral and Social Sciences. 2014:357-379. http://www.stat.cmu.edu/~hseltman/309/Book/ chapter15.pdf
12. Kremer JM, Weinblatt ME, Bankhurst AD, et al. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. Arthritis Rheum 2003;48:1493-9.
13. Klarenbeek NB, Van Der Kooij SM, Guler-Yuksel M, et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis 2011;70:315-19.
14. Fleischmann RM, Cohen SB, Moreland LW, et al. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial. Curr Med Res Opin 2005;21:1181-90.
15. Pope JE, Haraoui B, Thorne JC, et al. The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis. Ann Rheum Dis 2014;73:2144-51.
16. Kristensen LE, Saxne T, Nilsson JA, et al. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther 2006;8:R174.
17. Soliman MM, Ashcroft DM, Watson KD, et al. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011;70:583-9.
18. Burmester GR, Kivitz AJ, Kupper H, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis 2015;74:1037-44.
19. Manders SH, Kievit W, Adang E, et al. Effectiveness of TNF inhibitor treatment with various methotrexate doses in patients with rheumatoid arthritis: results from clinical practice. Ann Rheum Dis 2015;74:e24.